Disease modifying treatment in multiple sclerosis.
Fuller
G N
GN
Department of Neurology, Gloucester Royal Hospital, UK. geraint@fullerg.demon.co.uk
Bone
I
I
D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a